Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Nitric oxide Stories

2012-02-06 09:17:00

HAMPTON, N.J., Feb. 6, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 14th Annual BIO CEO & Investor Conference. Mr. Tasse's presentation will be given on Monday, February 13, 2012 at 3:30 p.m. EST in the Park South of the...

2012-01-31 08:19:00

COCOA, Fla., Jan. 31, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced it has been awarded one new US patent for its proprietary Nitric Oxide generation and delivery technology. This patent brings the company's total issued US patents to ten. GeNO's tenth patent (8,083,997) on NITROSYL(TM) (nitric oxide) for inhalation concerns the conversion of nitrogen dioxide (NO2) to nitric oxide (NO)...

2012-01-23 09:17:00

HAMPTON, N.J., Jan. 23, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse® DS drug-delivery system as a combination product for pulmonary arterial hypertension (PAH). An investigational new drug application...

2012-01-19 08:21:00

COCOA, Fla., Jan. 19, 2012 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced the hiring of four new senior executives as well as two promotions. The additions add significant management talent and capability to the company. In a series of moves that more than doubles GeNO's executive management team, the company today announced the hiring of: Kurt Dasse, Ph.D., former President and Founder of recently-sold...

2012-01-11 10:01:00

BOULDER, Colo., Jan. 11, 2012 /PRNewswire/ -- Clarimedix, Inc., a privately held company focused on the development of non-invasive therapeutics for the treatment of disorders associated with vascular dysfunction, today announced that an investment has been secured from the Johnson & Johnson Corporate Office of Science and Technology (COSAT). Financial terms of the deal are not disclosed. The funds secured from this investment will be used for a human proof-of-concept...

2011-12-15 08:45:00

COCOA, Fla., Dec. 15, 2011 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced it has been awarded two new US patents. The Company now has a total of nine issued US patents for its proprietary Nitric Oxide generation and delivery technology. GeNO's eighth patent (8,057,742) on NITROSYL(TM) (nitric oxide) for inhalation concerns the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) using the GeNO...

2011-12-06 07:15:00

WARRINGTON, Pa., Dec. 6, 2011 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today released new data showing that use of AFECTAIR® resulted in as much as a 70 percent reduction in the amount of nitric oxide required to deliver the desired dose of the therapeutic gas when compared with current standard of care (SoC) (p < 0.001). Nitric oxide is a costly medical gas frequently used for the treatment of pulmonary hypertension in newborn infants. AFECTAIR, the...

2011-10-26 13:00:00

Healthhound.org releases their report on Force Factor ingredients and give away a viable alternative to the supplements. Houston, TX. (PRWEB) October 26, 2011 Healthhound.org has released their long awaited report this week on the Force Factor ingredients and if the reaction on the health related blogs is anything to go by, there certainly are many people that have been awaiting for this report with bated breath. Healthhound.org has built a reputation for itself as a leading authority when...

2011-10-24 15:58:26

It is well known that smoking leads to a reduction in levels of fractional exhaled nitric oxide (FeNO), which is a marker for airway inflammation. However, there is limited knowledge about smoking-induced changes in the production and exchange of nitric oxide (NO) in young adults. In a study of eight women and eight men with a mean age of 23 years and a smoking history of less than eight pack-years, Greek researchers found that after smoking a single cigarette, the airway tissue...

2011-10-13 11:42:10

By studying mice exposed to tobacco smoke for a period of months, researchers have new insight into how emphysema and chronic obstructive pulmonary disease (COPD) develops. In the October 14th issue of Cell, a Cell Press publication, they also report a promising new way to reverse the lung damage underlying these conditions. "It has not been very clear what causes the disease and there has been no therapy to stop or reverse lung destruction in emphysema," said Norbert Weissman of the...